Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;9(4):195-9.
doi: 10.1016/j.autrev.2009.07.004. Epub 2009 Jul 27.

Malignancies in systemic lupus erythematosus

Affiliations
Review

Malignancies in systemic lupus erythematosus

Emese Kiss et al. Autoimmun Rev. 2010 Feb.

Abstract

Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease, characterized by a wide array of symptoms and organ involvements, leading to varying disease courses and outcome, and ranging from mild to severe types. In patients with SLE, the incidence and risk of malignancy development is increased, and mostly non-Hodgkin's lymphoma (NHL), cervical cancer, as well as bronchial carcinomas occur. Besides others, the common genetic predisposition, chronic antigen stimulus, disproportional immune responses, as well as the chronic administration of immunosuppressive medications can contribute to the development of malignancies in lupus. In this review we present the molecular pathology, as well as the epidemiological and clinical aspects of malignancies in patients with SLE.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Bernatsky S, Boivin J, Lawrence J, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005;52:1481–1490. - PubMed
    1. Parikh-Patel A, White RH, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control. 2008;19:887–894. - PMC - PubMed
    1. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:761–768. - PubMed
    1. Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol. 2002;31:66–71. - PubMed
    1. Bernatsky S, Clarke A, Petri MA, et al. Further defining cancer risk in systemic lupus: updated results in an expanded international multi-centre cohort. Arthritis Rheum. 2010;62:S731. Updated cohort study based on recent data regarding cancer in patients with systemic lupus erythematosus (SLE)

MeSH terms

Substances